Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ARVN Arvinas > Detailed Quotes

ARVN Arvinas

Watchlist
37.200
+0.020+0.05%
Trading Session  12/09 11:07 ET
High
37.370
Open
37.000
Turnover
1.59M
Low
36.510
Pre Close
37.180
Volume
43.07K
Market Cap
1.98B
P/E(TTM)
Loss
52wk High
83.400
Shares
53.23M
P/E(Static)
Loss
52wk Low
34.900
Float Cap
1.51B
Bid/Ask %
33.33%
Historical High
108.465
Shs Float
40.70M
Volume Ratio
0.45
Historical Low
10.190
Dividend TTM
--
Div Yield TTM
--
P/B
3.19
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.11%
Amplitude
2.31%
Avg Price
36.920
Lot Size
1
Float Cap
1.51B
Bid/Ask %
33.33%
Historical High
108.465
Shs Float
40.70M
Volume Ratio
0.45
Historical Low
10.190
Dividend TTM
--
P/B
3.19
Dividend LFY
--
Turnover Ratio
0.11%
Amplitude
2.31%
Avg Price
36.920
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
CEO: Dr. John G. Houston, PhD
Market: NASDAQ
Listing Date: 09/27/2018
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist